Sunday 18 October 2026
Export ARTV’s income statement to Excel — free account
Artiva Biotherapeutics, Inc.
ARTV Healthcare Biotechnology
Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023. In the quarter to June 2026, EPS grew 27.6% and free cash flow grew 13.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.85
0.21
−3.47%
Follow ARTV
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(47.96%) | (56.55%) | (67.86%) | (36.58%) | |
| (42.29%) | (49.26%) | (58.59%) | (33.76%) | ||
ROIC |
(860.60%) | (2,860.92%) | (5,403.11%) | 0.00% | |
Return on Tangible Assets |
(63.16%) | (78.97%) | (103.56%) | (26.45%) | |
Average Days of Receivables |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(3.22) | (3.25) | (3.25) | (1.95) | |
Free Cash Flow |
(78.90) | (79.34) | (80.18) | (76.91) | |
Capital Expenditures |
(2.23) | (2.59) | (2.32) | (1.68) | |
| Other line items | |||||
Cash ROIC |
(31.29%) | (36.40%) | (45.91%) | (11.04%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.97 | 0.92 | 0.89 | 0.83 | |
Depreciation/Fixed assets |
0.36 | 0.39 | 0.42 | 0.47 | |
Capex/Depreciation |
(0.88) | (1.00) | (0.88) | (0.62) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.13) | (3.14) | (3.15) | (1.91) | |
Capex per Share |
(0.09) | (0.11) | (0.09) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates